Nonetheless, tumors harboring EGFR mutations frequently have a reduced percentage group of CD8+ tumor-infiltrating lymphocytes (TILs) (77, 81), which may result in immunological dysfunction and a poor prognosis (82). The gene discussed is CD8A; the disease is neoplasm.